Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism in this clinical trial publication.

Twenty-nine patients underwent preoperatively the calcium infusion test to evaluate the PTH-Ca(2+) set-point.

Why It Was Studied

The intensity of CaR staining was not related to preoperative serum Ca(2+), PTH levels or adenoma volume.

Who Took Part

The abstract describes 4 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

What Was Measured

The intensity of CaR staining was not related to preoperative serum Ca(2+), PTH levels or adenoma volume.

The subject headings attached to it are Adenoma, Blotting, Western, Calcium, Hyperparathyroidism, Immunohistochemistry, Parathyroid Glands and Parathyroid Hormone.

What This Means in Plain Language

This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 4 patients in people with hyperparathyroidism.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.